Arecor Therapeutics plc
("Arecor" or "the Company")
APPOINTMENT OF INTERIM CHIEF FINANCIAL OFFICER
Cambridge, UK, 18 November 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, today announces the appointment of David Ellam as Interim Chief Financial Officer (CFO), effective immediately.
David is an experienced finance professional and chartered accountant, with over two decades of experience in the life sciences industry. He has held CFO roles at numerous healthcare companies including Juvenescence, a life sciences company developing therapies to modify ageing and increase healthy human lifespan, Silence Therapeutics, a biotechnology company harnessing the body's natural mechanism of RNA interference (RNAi) and, more recently, Sixfold Bioscience, a company focused on RNA delivery using AI/ML. Early in his career, he qualified as an accountant at PwC, transitioning to a variety of financial and internal audit roles at companies including Smith & Nephew.
Sarah Howell, Chief Executive Officer of Arecor, said: "David is a highly experienced finance executive whose life sciences knowledge and broad financial expertise will be highly valuable in supporting the business moving forward including as we continue to execute our strategic initiatives to drive shareholder value. It is my pleasure to welcome him to the Arecor team."
-ENDS-
For more information, please contact:
|
Arecor Therapeutics plc |
|
|
Dr Sarah Howell, Chief Executive Officer |
Tel: +44 (0) 1223 426060 Email: info@arecor.com |
|
|
|
|
Panmure Liberum Limited (NOMAD and Joint Broker) |
|
|
Emma Earl, Freddy Crossley, Mark Rogers (Corporate Finance) Rupert Dearden (Corporate Broking) |
Tel: +44 (0) 20 7886 2500
|
|
WG Partners LLP (Joint Broker) |
|
|
Nigel Barnes, Satheesh Nadarajah David Wilson, Claes Spang |
Tel: +44 (0)203 705 9321 |
|
|
|
|
ICR Healthcare |
|
|
Chris Gardner, David Daley, Lindsey Neville |
Tel: +44 (0) 20 3709 5700 Email: arecor@consilium-comms.com |
|
|
|
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.
For further details please see our website, www.arecor.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
